Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Yeku, Oladapo O ^a   Purdon, Terence J ^a   Koneru, Mythili ^a   Spriggs, David ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, MOUSE; INTERLEUKIN 12; PROGRAMMED DEATH 1 LIGAND 1;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; APOPTOSIS; ASCITES; C57BL MOUSE; CELL CULTURE; FEMALE; IMMUNOLOGY; METABOLISM; MOUSE; OVARY TUMOR; PROCEDURES; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; ASCITES; B7-H1 ANTIGEN; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; RECEPTORS, CHIMERIC ANTIGEN; TUMOR MICROENVIRONMENT;

EID: 85028852213     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10940-8     Document Type: Article

References (54)

1. Davila, M. L. et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361-71 (2014).
2. Park, J. R. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825-33 (2007).
3. Feng, K. et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci. China. Life Sci. 59, 468-79 (2016).
4. Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112-20 (2014).
5. Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-15 (2006).
6. Junghans, R. P. et al. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate 76, 1257-70 (2016).
7. Hwu, P. et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 178, 361-6 (1993).
8. Hwu, P. et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55, 3369-73 (1995).
9. Kim, S., Kim, B. & Song, Y. S. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 107, 1173-8 (2016).
10. Chen, L. et al. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J. Obstet. Gynaecol. Res. 35, 212-8 (2009).
11. Zhao, X., Ye, F., Chen, L., Lu, W. & Xie, X. Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+ CD25-CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro. Cancer Sci. 100, 2143-51 (2009).
12. Li, X. et al. Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer Lett. 253, 144-53 (2007).
13. Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. & Ostrand-Rosenberg, S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179, 977-83 (2007).
14. Bak, S. P., Alonso, A., Turk, M. J. & Berwin, B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol. Immunol. 46, 258-68 (2008).
15. Quatromoni, J. G. & Eruslanov, E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am. J. Transl. Res. 4, 376-89 (2012).
16. Auer, K. et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget 7, 61336-61354 (2016).
17. Liu, Y. et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol. Immunother. 58, 687-97 (2009).
18. Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. & Yang, R. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin. Immunol. 129, 471-81 (2008).
19. Wang, X., Teng, F., Kong, L. & Yu, J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco. Targets. Ther. 9, 5023-39 (2016).
20. Hamanishi, J. et al. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin. Immunol. 141, 338-47 (2011).
21. Sadelain, M., Brentjens, R. & Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-98 (2013).
22. Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563-74 (2009).
23. Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413-20 (2010).
24. Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901-9 (2008).
25. Yeku, O. O. & Brentjens, R. J. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell antitumour efficacy. Biochem. Soc. Trans. 44, 412-8 (2016).
26. Zhao, J., Zhao, J. & Perlman, S. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One 7, e46241 (2012).
27. Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression. Cancer Res. 71, 5697-5706 (2011).
28. Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-57 (2011).
29. Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672-83 (2012).
30. Atkins, M. B. et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-17 (1997).
31. Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541-8 (1997).
32. Hurteau, J. A., Blessing, J. A., DeCesare, S. L. & Creasman, W. T. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. 82, 7-10 (2001).
33. Lenzi, R. et al. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease > 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J. Transl. Med. 5, 66 (2007).
34. Kerkar, S. P. et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70, 6725-34 (2010).
35. Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278-88 (2015).
36. Chekmasova, A. A. et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16, 3594-606 (2010).
37. Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015).
38. Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133-41 (2012).
39. Lisiero, D. N., Soto, H., Liau, L. M. & Prins, R. M. Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12-Primed CD8+ T Cells in a Melanoma Model. doi.org 186, 5068-5077 (2011).
40. Zhang, X. & Starnbach, M. N. An Excess of the Proinflammatory Cytokines IFN-γ and IL-12 Impairs the Development of the Memory CD8+ T Cell Response to Chlamydia trachomatis. J. Immunol. 195, 1665-75 (2015).
41. Hodge, D. R., Hurt, E. M. & Farrar, W. L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502-12 (2005).
42. Duluc, D. et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110, 4319-30 (2007).
43. Shanker, A., Singh, S. M. & Sodhi, A. Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. FEMS Immunol. Med. Microbiol. 27, 247-55 (2000).
44. Platten, M., von K Doeberitz, N., Oezen, I., Wick, W. & Ochs, K. Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. Front. Immunol. 5, 673 (2014).
45. Vig, M. et al. Inducible nitric oxide synthase in T cells regulates T cell death and immune memory. J. Clin. Invest. 113, 1734-42 (2004).
46. Oelkrug, C. & Ramage, J. M. Enhancement of T cell recruitment and infiltration into tumours. Clin. Exp. Immunol. 178, 1-8 (2014).
47. Colvin, E. K. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front. Oncol. 4, 137 (2014).
48. Watkins, S. K., Egilmez, N. K., Suttles, J. & Stout, R. D. IL-12 rapidly alters the functional profile of tumor-associated and tumorinfiltrating macrophages in vitro and in vivo. J. Immunol. 178, 1357-62 (2007).
49. Dalton, J. E., Howell, G., Pearson, J., Scott, P. & Carding, S. R. Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells. J. Immunol. 173, 3660-7 (2004).
50. Abiko, K. et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501-9 (2015).
51. Abiko, K. et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19, 1363-74 (2013).
52. Lenzi, R. et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin. Cancer Res. 8, 3686-95 (2002).
53. Grohmann, U. et al. Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J. Immunol. 167, 221-7 (2001).
54. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184-91 (2016).